Mary Haak-Frendscho, Ph.D. has been appointed president and chief scientific officer, Takeda San Francisco, Inc. Dr. Haak-Frendscho will be responsible for leading all activities at the company, including overall research and preclinical development, process development studies and operations for antibody therapeutics. Takeda San Francisco, established in November 2007, is a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. of Osaka, Japan.      
   
"Dr. Haak-Frendscho's strong leadership skills and biotechnology experience will greatly contribute to the success of Takeda San Francisco," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda. "Takeda San Francisco will play an increasingly critical role in the expansion of Takeda's R&D capabilities as we look to promote the development of antibody therapeutics, and I am confident that Dr. Haak-Frendscho will help us realize our goals in the antibody field."
   
Dr. Haak-Frendscho has more than 17 years of pharmaceutical and biotechnology experience having held positions at Genentech, Abgenix and most recently, at XOMA, where she served as chief science officer and vice president, preclinical R&D.

William J. Conroy has been appointed vice president of operations and engineering at Microfluidics, a wholly owned subsidiary of MFIC Corp. In this position, Mr. Conroy will have P/L responsibility for the operating division of both Microfluidics and MFIC, including product design and engineering, production and purchasing. Mr. Conroy will also assume responsibility for overall systems quality and reliability, and will report directly to Michael C. Ferrara, chief executive officer.
   
Mr. Conroy has more than 25 years of high-tech product management, quality control and operations experience. Most recently, he served as senior vice president of production and operations at RemoteReality Corp., which designs and manufactures products for the military/defense and securities business sectors. Mr. Conroy has also held senior level operations, manufacturing and quality control positions at Northrop Grumman (formerly Fibersense Technology Corp.), Karl Storz Endovision, Circon ACMI and Kohler Co.  

DOR BioPharma has opened a new corporate office in the UK. The new office gives DOR a presence in the EU to better facilitate the Named Patient Access program that will be administered by IDIS, also based in the UK. Serving as the company's official interface for regulatory interactions within the EU, the office will operate as DOR BioPharma UK Ltd. and will be located at: BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire.
   
"The new DOR UK office gives us a multinational presence that we have not previously had," said Christopher J. Schaber, Ph.D., President and CEO of DOR. "This new office will aid us in achieving our strategic vision of making orBec available to patients throughout Europe through our Named Patient Access programs while we conduct our confirmatory Phase III clinical trial. It also has the potential to facilitate the conduct of new clinical trials in Europe as well as to provide support to European business relationships in the future."